occlus
bodi
special
baculoviru
vector
mammalian
promot
express
antigen
immun
individu
histor
overview
show
wide
varieti
viral
glyco
protein
success
express
system
vaccin
purpos
potenti
express
system
antiparasit
vaccin
illustr
combin
subunit
vaccin
marker
test
base
antigen
express
insect
cell
provid
power
tool
combat
diseas
monitor
infecti
agent
histor
vaccin
one
costeffect
easili
administ
mean
control
infecti
diseas
human
anim
vaccin
develop
root
work
edward
jenner
discov
man
could
protect
smallpox
inocul
cowpox
fenner
work
loui
pasteur
develop
first
rabi
vaccin
fu
pioneer
effort
led
vaccin
diseas
claim
million
live
worldwid
andr
childhood
vaccin
program
common
practic
elabor
vaccin
program
set
world
health
organ
lead
offici
erad
smallpox
fenner
today
larg
part
world
also
declar
poliomyel
free
measl
next
target
erad
vaccin
control
major
bacteri
viral
diseas
human
effect
vaccin
avail
mani
andr
hansson
et
al
vaccin
also
protect
livestock
pet
anim
pastoret
et
al
diseas
howev
malaria
acquir
immunodefici
syndrom
aid
vaccin
despar
sought
human
anim
vaccin
base
kill
liveattenu
pathogen
kill
vaccin
requir
product
larg
amount
often
highli
virul
pathogen
type
vaccin
therefor
riski
produc
anoth
risk
lie
potenti
incomplet
inactiv
pathogen
inactiv
hand
affect
immunogen
properti
pathogen
henc
efficaci
vaccin
often
difficult
find
balanc
effici
inactiv
conserv
immunogen
liveattenu
vaccin
consist
pathogen
reduc
virul
attenu
either
grow
altern
host
unfavor
grow
condit
recombin
dna
technolog
liveattenu
vaccin
potenti
replic
host
typic
attenu
pathogen
avoid
develop
sever
diseas
live
vaccin
elicit
humor
cellular
immun
may
provid
lifelong
protect
singl
dose
dertzbaugh
hansson
et
al
schijn
longterm
protect
advantag
develop
countri
individu
often
immun
drawback
liveattenu
vaccin
caus
side
effect
may
danger
use
prophylaxi
immunocompromis
person
elderli
individu
genet
acquir
diseas
immun
system
eg
aid
sever
combin
immunodefici
scid
liveattenu
vaccin
may
also
convert
virul
strain
spread
nonimmun
person
observ
recent
poliomyel
outbreak
kew
et
al
advers
effect
kill
liveattenu
vaccin
also
due
allerg
reaction
compon
vaccin
residu
egg
protein
case
influenza
vaccin
kelso
yunging
gelatin
measlesmumpsrubella
mmr
vaccin
patja
et
al
develop
vaccin
easi
infecti
diseas
medic
veterinari
world
challeng
frequent
emerg
novel
diseas
aid
sever
acut
respiratori
syndrom
sar
west
nile
viru
infect
vaccin
industri
constant
pressur
rapidli
chang
pathogen
larg
amount
vaccin
need
annual
influenza
virus
pales
flexibl
vaccin
product
techniqu
requir
sever
infecti
diseas
vaccin
develop
use
convent
approach
instanc
due
lack
appropri
anim
product
system
highmut
frequenc
pathogen
human
immunodefici
viru
hiv
malaria
vaccin
influenza
strain
current
epidem
asian
poultri
could
produc
classic
way
use
embryon
chicken
egg
without
reduc
virul
viru
revers
genet
due
highmort
rate
chicken
embryo
horimoto
et
al
recombin
protein
product
system
may
provid
good
altern
develop
vaccin
difficult
produc
vivo
manufactur
socal
subunit
vaccin
pathogen
consist
mani
protein
frequent
carbohydr
moieti
equal
import
gener
adequ
immunolog
respons
subunit
vaccin
contain
immunodomin
compon
pathogen
case
viral
vaccin
often
glyco
protein
viral
coat
envelop
hepat
b
surfac
antigen
valenzuela
et
al
classic
swine
fever
viru
csfv
glycoprotein
bouma
et
al
viral
coat
protein
sometim
form
viruslik
particl
vlp
express
heterolog
system
brown
et
al
often
immunogen
may
induc
humor
cellular
respons
subunit
vaccin
hepat
b
produc
yeast
highli
succes
extrem
exampl
subunit
vaccin
peptidebas
vaccin
consist
small
amino
acid
chain
harbor
part
antigen
protein
recogn
antibodi
typic
subunit
vaccin
contain
genet
materi
pathogen
small
part
thereof
therefor
vaccin
caus
diseas
introduc
pathogen
nonendem
region
addit
advantag
subunit
vaccin
use
combin
specif
marker
test
make
possibl
differenti
infect
vaccin
anim
socal
diva
vaccin
capua
et
al
van
oirschot
import
issu
monitor
viru
preval
virusfre
export
anim
product
immunogen
subunit
isol
chemic
pathogen
purifi
capsular
polysaccharid
present
streptococcu
pneumonia
vaccin
merck
process
still
requir
product
virul
pathogen
without
risk
altern
use
recombin
dna
technolog
produc
protein
subunit
heterolog
system
varieti
express
system
avail
clark
cassidyhanley
hansson
et
al
yeast
system
saccharomyc
cerevisia
instanc
use
produc
hepat
b
subunit
vaccin
valenzuela
et
al
current
licens
recombin
subunit
vaccin
human
use
yeast
pichia
pastori
use
product
antitick
vaccin
gavac
tm
canal
et
al
protect
cattl
tick
boophilu
microplu
transmitt
babesia
anaplasma
parasit
speci
insect
cell
use
produc
vaccin
classic
swine
fever
hog
cholera
depner
et
al
van
aarl
product
recombin
protein
higher
eukaryot
mammalian
insect
plant
express
system
avail
either
use
trangen
viral
vector
protein
express
plant
recogn
product
socal
edibl
subunit
vaccin
administ
ingest
veget
food
et
al
streatfield
howard
chapter
concentr
use
cultur
insect
cell
larva
combin
baculoviru
express
vector
product
subunit
vaccin
baculoviru
express
system
accept
welldevelop
system
product
viral
antigen
vaccin
potenti
dertzbaugh
hansson
et
al
vlak
keu
system
also
explor
develop
vaccin
protozoan
parasit
kaba
et
al
therapeut
vaccin
tumor
vaccin
prostatecanc
proveng
phase
iiiii
clinic
trial
base
combin
recombin
prostat
acid
phosphatas
characterist
prostat
cancer
patient
dendrit
cell
immun
beinart
et
al
rini
trial
also
initi
prophylact
vaccin
use
vlp
produc
insect
cell
cervic
cancer
caus
human
papillomaviru
hpv
mao
et
al
express
system
advantag
drawback
tabl
system
choic
depend
much
specif
requir
particular
vaccin
often
base
least
partli
trial
error
definit
choic
made
express
level
achiev
adequaci
posttransl
modif
immunolog
perform
possibilit
scaleup
cost
risk
contamin
method
administr
legal
aspect
must
taken
account
baculovirusinsect
cell
express
system
smith
et
al
develop
product
biolog
activ
glyco
protein
wellestablish
safe
eukaryot
environ
kost
et
al
famili
baculovirida
contain
rodshap
invertebrateinfect
virus
larg
doublestrand
coval
close
circular
dna
genom
tabl
ii
member
larg
viru
famili
taxonom
divid
genera
nucleopolyhedroviru
npv
granuloviru
gv
base
occlus
bodi
morpholog
theilmann
et
al
npv
express
two
gene
polyhedrin
high
level
late
phase
infect
polyhedrin
protein
form
viral
occlus
bodi
polyhedra
present
fibrillar
structur
function
polyhedron
morpholog
breakdown
infect
cellnuclei
releas
polyhedra
okano
et
al
van
oer
vlak
two
gene
essenti
viru
replic
cell
cultur
therefor
promot
exploit
drive
foreign
gene
express
form
basi
baculovirusinsect
cell
express
system
sinc
baculovirus
rodshap
larg
amount
foreign
dna
accommod
within
viru
particl
contrast
vaccinia
especi
adenoviru
express
vector
tabl
ii
type
member
npv
autographa
californica
multipl
nucleopolyhedroviru
acmnpv
viru
genom
kilobas
pair
ayr
et
al
baculoviru
routin
use
foreign
gene
express
baculoviru
bombyx
mori
npv
use
vaccin
purpos
much
lesser
extent
choi
et
al
mori
et
al
baculoviru
express
vector
replic
cultur
insect
cell
larva
high
yield
heterolog
protein
gener
obtain
strong
viral
polyhedrin
promot
exploit
king
posse
oreilli
et
al
insect
cell
line
use
baculoviru
express
system
deriv
lepidopteran
insect
moth
often
spodoptera
frugiperda
line
trichoplusia
ni
high
five
tm
cell
use
combin
acmnpvbas
vector
b
mori
cell
eg
use
bmnpv
insect
cell
line
vari
characterist
term
growth
rate
protein
product
secret
effici
glycosyl
pattern
interfer
viral
genom
stabil
pijlman
et
al
vlak
et
al
insect
cell
rel
easi
maintain
mani
grow
equal
well
suspens
larg
volum
l
reaction
high
densiti
solid
support
cultiv
serumfre
media
facilit
purif
recombin
protein
unlik
mammalian
cell
requir
co
easili
withstand
temperatur
fluctuat
extra
advantag
chanc
contamin
human
mammalian
virus
especi
serumfre
cultur
small
compar
mammalian
product
system
vertebr
virus
replic
lepidopteran
cell
cell
support
growth
mammalian
mycoplasma
either
instead
insect
cell
whole
insect
larva
may
use
live
bioreactor
vaccin
product
use
whole
insect
larva
advantag
simpl
insectrear
technolog
downstream
process
exploit
vivo
product
could
perform
smallscal
local
industri
especi
larva
fed
directli
anim
experiment
newcastl
diseas
vaccin
chicken
mori
et
al
vaccin
less
well
defin
howev
qualiti
control
may
therefor
difficult
achiev
express
protein
insect
cell
allow
appropri
fold
posttransl
modif
oligomer
therefor
biolog
activ
normal
preserv
protein
glycosyl
insect
mammal
ident
though
nglycanprocess
pathway
insect
result
glycoprotein
paucimannos
glycan
group
contrast
mammalian
glycoprotein
contain
complex
sialyl
glycan
see
also
harrison
volum
exact
glycan
composit
vari
differ
insect
cell
line
kost
et
al
tomiya
et
al
gener
glycan
group
immunogen
therefor
seem
major
disadvantag
subunit
vaccin
situat
authent
glycosyl
requir
instanc
preserv
function
activ
transform
human
insect
cell
line
express
mammalian
glycosyl
enzym
avail
jarvi
kost
et
al
tomiya
et
al
insect
cell
line
report
fucos
group
ad
nglycan
impact
remain
determin
sinc
fucan
may
caus
allerg
reaction
may
point
consider
choos
insect
cell
line
vaccin
product
long
et
al
tomiya
et
al
origin
baculoviru
express
system
base
allel
exchang
baculoviru
polyhedrin
gene
heterolog
gene
recombin
insect
cell
smith
et
al
similar
way
baculoviru
vector
sinc
develop
exploit
nonessenti
late
baculoviru
promot
weyer
posse
vector
leav
polyhedrin
gene
intact
use
product
recombin
protein
insect
larva
fig
vivo
recombin
protocol
improv
use
linear
viral
dna
allel
replac
result
domin
select
much
higher
percentag
recombin
virus
kitt
et
al
marten
et
al
vector
type
bacpak
tm
vector
baculogold
tm
bacnblu
tm
linear
viral
dna
carri
lethal
delet
becom
replic
compet
recombin
transfer
plasmid
carri
foreign
gene
therebi
restor
delet
kitt
posse
baculoviru
vector
base
gateway
technolog
baculodirect
tm
linear
baculoviru
vector
foreign
gene
introduc
sitespecif
vitro
recombin
time
anoth
effici
rapid
method
gener
recombin
baculovirus
develop
luckow
et
al
employ
transposit
foreign
gene
express
cassett
donor
plasmid
bacteri
artifici
chromosom
bac
contain
entir
acmnpv
genom
bacmid
system
bactobac
tm
recombin
baculoviru
genom
gener
escherichia
coli
use
transfect
insect
cell
obtain
recombin
baculoviru
particl
gener
hightit
viru
stock
insect
cell
infect
produc
recombin
protein
bacmidbas
methodolog
time
gener
recombin
virus
reduc
consider
anoth
advantag
recombin
bacmid
store
e
coli
recov
need
disadvantag
bacteri
gene
cassett
present
bacmidderiv
virus
may
easili
lost
viru
passag
pijlman
et
al
addit
acmnpv
bacmid
also
construct
spodoptera
exigua
mnpv
helicoverpa
armigera
snpv
pijlman
et
al
wa
n
g
et
al
h
e
os
r
ec
en
et
ho
c
om
bi
ne
b
ac
mi
technolog
allel
replac
flashbac
tm
oxford
express
technolog
therebi
remov
bac
sequenc
viral
genom
latter
system
especi
suitabl
highthroughput
screen
year
novel
baculoviru
vector
develop
special
featur
specif
applic
transfer
vector
modifi
express
polyhistidinetag
protein
easi
purif
pfastbachi
tm
transfer
vector
dual
tripl
quadrupl
promot
usual
polyhedrin
develop
allel
replac
belyaev
roy
weyer
posse
dual
pfastbacdu
tm
quadrupl
vector
tareilu
et
al
also
develop
bacmid
technolog
multipl
vector
use
express
variou
protein
simultan
henc
use
produc
multimer
complex
includ
viral
capsid
consist
one
viral
protein
belyaev
roy
balanc
express
level
sometim
problem
vector
may
requir
coinfect
vector
express
domin
protein
modif
promot
one
promot
multipl
promot
vector
may
use
express
report
gene
green
fluoresc
protein
gfp
make
easi
follow
infect
process
cell
perform
viru
titrat
track
baculoviru
infect
insect
cha
et
al
kaba
et
al
recent
develop
vector
system
ultrabac
use
baculoviru
late
basic
protein
promot
express
gfp
togeth
foreign
gene
allow
earlier
monitor
infect
philipp
et
al
baculoviru
surfac
display
vector
grabherr
et
al
expos
antigen
surfac
bud
baculoviru
particl
achiev
fuse
foreign
antigen
baculoviru
envelop
glycoprotein
monsma
et
al
chimer
protein
transport
cell
membran
taken
viral
envelop
bud
system
also
combin
bacmid
technolog
kaba
et
al
recombin
bud
viru
bv
particl
lysat
cell
infect
display
vector
shown
evok
protect
immun
respons
kaba
et
al
tami
et
al
yoshida
et
al
baculoviru
vector
express
foreign
gene
fusion
polyhedrin
along
wildtyp
polyhedrin
allow
incorpor
antigen
baculoviru
occlus
bodi
je
et
al
occlus
bodi
stabl
easi
purifi
use
directli
immun
wilson
et
al
express
surfac
glyco
protein
go
export
pathway
gener
difficult
express
solubl
cytoplasm
protein
result
much
lower
yield
van
oer
et
al
increas
product
level
surfac
protein
often
express
secret
protein
remov
hydrophob
transmembran
region
tmr
serv
anchor
protein
cell
membran
remov
domain
recombin
dna
technolog
lead
secret
protein
purifi
cultur
medium
howev
caution
need
approach
may
affect
fold
vaccin
efficaci
protein
present
surfac
nativ
condit
automat
transport
cell
surfac
express
insect
cell
surfac
protein
bovin
parasit
theileria
parva
nene
et
al
origin
signal
peptid
replac
insect
analogu
honeybe
mellitin
signal
peptid
tessier
et
al
properli
rout
cell
surfac
kaba
et
al
similar
rout
export
pathway
could
obtain
fusion
surfac
display
vector
kaba
et
al
signal
peptid
direct
protein
cell
surfac
membran
secret
protein
pass
endoplasm
reticulum
er
golgi
apparatu
way
cell
surfac
may
becom
glycosyl
process
abund
baculoviru
protein
chitinas
also
transport
er
accumul
due
kdel
retent
sequenc
savil
et
al
thoma
et
al
chitinas
express
late
phase
baculoviru
infect
involv
dissolut
insect
chitin
cuticl
enhanc
spread
viral
occlus
bodi
hawtin
et
al
delet
chitinas
baculoviru
vector
result
higher
level
secret
recombin
protein
posse
et
al
possibl
chitinas
clogg
protein
transloc
machineri
compet
recombin
secretori
protein
flashbac
system
describ
earlier
lack
chitinas
gene
anoth
baculoviru
protein
vcathepsin
also
accumul
er
activ
cell
death
proteolyt
cleavag
hom
et
al
process
provcathepsin
activ
cathepsin
also
trigger
chaotrop
agent
sodium
dodecyl
sulfat
may
result
proteolysi
recombin
protein
extract
purif
hom
volkman
bacmid
vector
lack
chitinas
vcathepsin
improv
stabil
secret
recombin
protein
therebi
increas
yield
fulllength
protein
molecul
kaba
et
al
fold
complic
transmembran
glycoprotein
improv
coexpress
molecular
chaperon
serotonin
transport
sert
protein
brain
glycoprotein
predict
transmembran
domain
coexpress
chaperon
calnexin
lesser
extent
immunoglobulin
heavi
chainbind
protein
bip
calreticulin
increas
yield
function
sert
threefold
foldas
effect
tate
et
al
calreticulin
calnexin
also
shown
increas
level
activ
lipoprotein
lipas
coexpress
insect
cell
stimul
dimer
recombin
protein
zhang
et
al
express
calnexin
calreticulin
stabl
transgen
insect
cell
line
infect
recombin
baculoviru
result
lower
ratio
secret
versu
intracellular
recombin
protein
cell
coinfect
two
baculovirus
one
carri
gene
interest
chaperon
kato
et
al
result
suggest
chaperon
express
level
order
recombin
protein
level
anoth
special
adapt
incorpor
mammalian
promot
baculoviru
vector
drive
foreign
gene
express
baculoviru
vector
mammalian
promot
bacmam
tm
virus
potenti
serv
gene
deliveri
vector
gene
therapi
huser
hofmann
kost
condreay
also
test
vaccin
purpos
abe
et
al
aoki
et
al
facciaben
et
al
poomputsa
et
al
case
mammalian
promot
viral
promot
activ
mammalian
cell
human
cytomegaloviru
hcmv
promot
drive
intracellular
express
antigen
exposur
cell
surfac
via
major
histocompat
complex
mhc
activ
cellular
immun
system
respect
type
vaccin
resembl
dna
vaccin
bacmam
tm
vector
produc
insect
cell
replic
incompet
mammalian
cell
tabl
ii
advantag
multipl
gene
insert
simultan
baculoviru
genom
allow
multival
vaccin
express
multipl
protein
advantag
baculoviru
express
system
system
especi
adenoviru
vector
maxim
increas
genom
size
limit
due
packag
restrict
manufactur
subunit
vaccin
largescal
product
unit
need
instanc
product
malaria
annual
influenza
subunit
vaccin
baculovirusinsect
cell
system
scaledup
largescal
cultur
either
fermentor
bioreactor
cellbag
devic
wave
reactor
insect
cell
bioreactor
l
report
bioprocess
technolog
behind
larg
scale
product
review
other
hunt
ikonom
et
al
vlak
et
al
problem
repeatedli
encount
expr
sing
recom
binan
protein
wit
h
baculo
viru
vector
drop
expr
sion
lev
el
wit
h
increa
ing
viru
passag
e
review
ed
kre
socal
passag
e
effect
intrins
bac
uloviru
replic
cell
cultur
less
critic
small
la
borat
yscal
e
prot
ein
produ
ction
number
viru
pass
age
low
signifi
cant
problem
thoug
h
largesca
le
indust
rial
produ
ction
vaccin
insect
cell
bioreact
or
van
lier
et
al
prevent
use
f
contin
bioreact
or
maj
cau
se
loss
f
recom
binant
prote
expr
sion
ar
e
mutati
on
gene
reduc
ing
activ
poli
hedrin
promot
harrison
et
al
th
e
gene
ration
defe
ctive
interf
ere
partic
le
di
whic
h
replica
te
th
e
expens
fullleng
th
recombin
ant
viru
kool
et
al
pijlman
et
al
wick
ham
et
al
intrac
llula
r
accumul
ation
concat
nate
viral
sequ
enc
exam
ple
nonhr
homo
log
ou
repeat
origin
f
dna
replic
ation
whic
h
terfer
wit
h
replic
ation
fulllength
geno
me
lee
krell
pijlm
et
al
sponta
neou
deleti
heterol
ogou
gene
th
e
baculov
iru
vector
latter
aspect
esp
cialli
seen
bac
midderi
ved
vec
tor
whic
h
extrem
eli
sen
itiv
sponta
neou
remov
expr
sion
cassett
larg
piec
dna
select
pijlman
et
al
prevent
amplif
di
baculoviru
vector
must
use
low
multipl
infect
moi
de
gooijer
et
al
wickham
et
al
common
practic
keep
number
viral
passag
minimum
establish
lowpassag
viru
bank
seed
stock
product
purpos
recent
year
sever
approach
use
improv
stabil
baculoviru
genom
accumul
nonhrcontain
sequenc
easili
prevent
remov
sequenc
baculoviru
backbon
pijlman
et
al
reduc
distanc
origin
replic
bacmid
system
insert
extra
hr
sequenc
within
express
cassett
also
result
prolong
foreign
gene
express
test
bioreactor
pijlman
et
al
flashbac
system
destabil
bacteri
deriv
sequenc
remov
recombin
transfer
vector
prevent
loss
foreign
gene
cassett
bicistron
vector
develop
contain
foreign
gene
baculoviru
essenti
gene
singl
bicistron
transcript
unit
link
intern
ribosom
entri
site
ire
delet
origin
locu
bicistron
vector
loss
foreign
gene
would
automat
result
loss
express
essenti
gene
need
gener
complet
viru
particl
well
di
gfp
express
level
kept
high
level
least
passag
vector
provid
domin
select
pijlman
et
al
system
await
test
express
protein
medic
import
combin
sever
method
describ
section
like
genom
stabil
improv
sinc
recognit
product
system
subunit
vaccin
vlak
keu
baculovirusinsect
cell
express
system
use
extens
express
candid
vaccin
antigen
comprehens
overview
viral
antigen
virus
vertebr
express
system
provid
tabl
iii
antigen
test
abil
induc
protect
immun
respons
includ
addit
mani
viral
antigen
success
express
insect
cell
develop
diagnost
perform
structur
function
studi
studi
exclud
chapter
variou
viral
antigen
rang
capsid
envelop
protein
nonstructur
protein
chosen
develop
subunit
vaccin
viral
antigen
divid
express
singl
oligomer
protein
subunit
selfassembl
vlp
differ
approach
vaccin
describ
exampl
later
special
attent
paid
influenza
subunit
vaccin
envelop
protein
synthes
singl
oligomer
subunit
express
envelop
protein
often
function
activ
report
oligomer
indic
correctli
fold
crawford
et
al
commonli
viral
envelop
glycoprotein
glycosyl
insect
cell
exampl
baculovirusproduc
subunit
vaccin
candid
tabl
iii
fusion
protein
hemagglutinin
paramyxovirus
newcastl
diseas
viru
e
protein
flavivirida
includ
west
nile
viru
dengu
virus
csfv
two
commerci
avail
veterinari
subunit
vaccin
classic
swine
fever
bayovac
csf
tm
porcili
pesti
tm
base
csfv
glycoprotein
produc
insect
cell
ahren
et
al
bouma
et
al
bouma
et
al
depner
et
al
van
aarl
envelop
glycoprotein
csfv
express
secret
protein
remov
tmr
result
threefold
increas
express
level
allow
purif
cultur
medium
hulst
et
al
similar
way
relat
bovin
diarrhea
viru
bvdv
protein
express
insect
cell
bolin
ridpath
recent
research
show
bvdv
protein
need
glycosyl
effect
secret
baculovirusinfect
cell
pand
et
al
glycosyl
protein
abl
block
bvdv
infect
better
vitro
assay
whether
glycosyl
protein
also
perform
better
vaccin
known
spike
glycoprotein
sar
coronaviru
one
recent
express
protein
insect
cell
protect
mice
intranas
sar
infect
bisht
et
al
influenza
present
seriou
risk
human
anim
health
singlestrand
rna
influenza
viru
chang
quickli
accumul
mutat
frequent
recombin
event
requir
annual
vaccin
updat
pales
threaten
recent
exampl
outbreak
avian
influenza
serotyp
kill
bird
human
far
east
sinc
caus
first
human
casualti
outsid
area
east
turkey
januari
big
fear
avian
viru
chang
viru
transmit
directli
man
man
may
lead
influenza
outbreak
pandem
dimens
pales
wide
use
influenza
vaccin
e
g
fluzon
sanofi
pasteur
fluvirin
chiron
consist
chemic
inactiv
split
viru
purifi
viru
subunit
vaccin
sever
disadvantag
recent
review
cox
cox
et
al
includ
reduc
efficaci
elderli
vaccin
reduc
mortal
rate
effect
prevent
diseas
addit
enorm
number
egg
need
year
one
egg
per
dose
like
lead
shortag
vaccin
event
pandem
strain
grow
poorli
egg
requir
coinfect
strain
genet
adapt
eg
horimoto
et
al
vaccin
caus
strong
allerg
reaction
individu
live
attenu
influenza
vaccin
advantag
induc
secretori
system
immun
appli
intranas
prevent
viru
replic
respiratori
tract
cox
et
al
howev
vaccin
still
need
grown
chicken
embryo
iron
also
target
potenti
pandem
viru
like
overcom
drawback
variou
cellbas
vaccin
influenza
develop
well
recombin
protein
vaccin
clinic
trial
vaccin
base
influenza
viru
produc
mammalian
cell
cultur
madin
darbi
canin
kidney
mdck
cell
describ
brand
et
al
percheson
et
al
trial
influenza
vaccin
produc
human
retina
cell
line
pau
et
al
ongo
product
still
requir
inactiv
influenza
viru
may
reduc
immunogen
seen
inactiv
vaccin
respons
human
casualti
influenza
virus
asia
late
immunogen
safeti
baculoviru
recombin
hemagglutinin
ha
protein
test
chicken
result
protect
diseas
symptom
crawford
et
al
immunogen
baculovirusderiv
vaccin
subsequ
evalu
healthi
human
adult
vaccin
well
toler
provid
neutral
antibodi
respons
equival
observ
convalesc
sera
individu
two
dose
treanor
et
al
clinic
trial
baculovirusproduc
recombin
antigen
adult
volunt
show
protect
neutral
antibodi
level
reduct
influenza
rate
follow
epidem
season
compar
placebo
group
power
et
al
habas
vaccin
induc
b
memori
cell
power
et
al
clinic
studi
individu
averag
age
year
complet
experiment
vaccin
protein
scienc
corpor
contain
three
ha
antigen
variant
present
licens
inactiv
vaccin
flu
season
treanor
et
al
compar
licens
vaccin
recombin
vaccin
produc
higher
antibodi
titer
strain
strain
respons
major
influenza
death
year
cox
result
suggest
vaccin
especi
use
reduct
annual
number
influenzarel
death
elderli
antibodi
titer
induc
convent
vaccin
low
protect
phase
iii
trial
healthi
adult
complet
show
protect
effcicaci
even
influenza
virus
manon
cox
person
commun
http
wwwproteinsciencescom
jan
prepar
recombin
influenza
viru
vaccin
cocktail
come
flu
season
may
take
month
complet
moment
new
vaccin
composit
announc
world
health
organ
inactiv
convent
vaccin
trival
recombin
habas
vaccin
develop
base
antibodi
respons
ha
surfac
protein
requir
annual
modif
vaccin
due
antigen
drift
influenza
viru
baculoviru
recombin
vaccin
ha
neuraminidas
na
subunit
result
bival
seroconvers
antibodi
ha
na
johansson
efficaci
vaccin
base
ha
na
produc
recombin
baculoviru
analyz
murin
model
compar
convent
kill
liveattenu
vaccin
prepar
ha
singlesubunit
vaccin
brett
johansson
na
baculovirusderiv
vaccin
much
immunogen
convent
vaccin
advantag
induc
immun
respons
surfac
protein
illustr
fact
recombin
vaccin
contain
ha
na
prevent
infect
homotyp
close
relat
virus
also
show
strong
reduct
pulmonari
viru
titer
infect
distantli
relat
viru
versu
contrast
vaccin
base
ha
result
suggest
vaccin
contain
intact
na
toler
antigen
drift
therebi
reduc
chanc
viru
escap
immun
system
flu
season
viral
capsid
protein
produc
insect
cell
often
selfassembl
vlp
advantag
vlp
resembl
natur
viru
infecti
lack
genet
materi
vlp
also
excel
tool
studi
viru
structur
vlp
easili
purifi
extract
centrifug
precipit
brown
et
al
often
give
strong
immun
reaction
even
absenc
adjuv
due
particul
natur
addit
humor
cellmedi
mucos
immun
respons
report
roy
exampl
vaccin
consist
recombin
vlp
produc
baculoviru
vector
patent
canin
parvoviru
vaccin
vald
et
al
sometim
express
one
viral
coat
protein
need
make
immunogen
vlp
either
due
complex
capsid
structur
bluetongu
viru
btv
reovirida
presenc
crucial
epitop
sever
coat
protein
multicompon
vlp
produc
use
vector
multipl
promot
coinfect
sever
baculoviru
vector
encod
one
viral
protein
one
difficulti
make
complex
vlp
achiev
appropri
express
level
protein
present
viral
capsid
capsid
protein
hepat
e
viru
calicivirida
form
vlp
vlp
induc
system
mucos
immun
oral
administr
mous
model
also
protect
cynomolgu
monkey
challeng
hev
infect
hepat
li
et
al
li
et
al
infecti
bursal
diseas
ibdv
birnavirida
bird
also
prevent
vaccin
singl
compon
vlp
martineztorrecuadrada
et
al
wang
et
al
major
capsid
protein
papovavirida
form
vlp
shown
protect
cottontail
rabbit
cottontail
rabbit
papillomaviru
combin
capsid
protein
oncogen
protein
protect
tumor
format
mous
model
greenston
et
al
multival
vlp
prepar
contain
btv
reovirida
subunit
variou
serotyp
made
coinfect
sever
baculoviru
vector
induc
longlast
protect
sheep
roy
et
al
vaccin
candid
form
vlp
four
differ
vp
also
success
produc
btv
pearson
roy
van
dijk
well
sever
reovirida
conner
et
al
b
immun
mice
influenza
vlp
contain
two
matrix
protein
surfac
protein
ha
na
show
almost
complet
protect
viru
via
intramuscular
intranas
immun
rout
galarza
et
al
rational
use
vlp
vaccin
candid
obviou
nonenvelop
virus
virus
capsid
protein
directli
expos
immun
system
howev
may
also
use
display
epitop
envelop
virus
hiv
envelop
viru
case
vlp
produc
base
gag
immunogen
segment
envelop
protein
coupl
arico
et
al
buonaguro
et
al
tobin
et
al
extens
chimer
vlpbase
vaccin
use
vlp
one
viru
display
epitop
heterolog
protein
form
vlp
exampl
system
human
parvoviru
vlp
carri
linear
epitop
fusion
viral
protein
system
use
display
epitop
murin
hepat
viru
mhv
coronavirida
herp
simplex
viru
hsv
herpesvirida
brown
et
al
chimer
vlp
protect
mice
lethal
challeng
mhv
hsv
epitopepres
chimer
vlp
also
develop
base
mous
papillomaviru
tegerstedt
et
al
flock
hous
viru
vlp
scodel
et
al
monoand
oligomer
protein
subunit
often
less
potent
need
formul
care
administr
extend
halflif
present
proper
form
immun
system
instanc
uptak
antigenpres
cell
apc
dertzbaugh
schijn
adjuv
possibl
human
applic
limit
safeti
consider
may
limit
applic
monomer
subunit
vaccin
human
vlp
hand
shown
induc
protect
even
without
addit
adjuv
li
et
al
roy
altern
way
modul
immun
respons
addit
recombin
cytokin
vaccin
adjuv
cytokin
either
ad
separ
vaccin
may
includ
vlp
approach
may
modul
magnitud
also
type
immun
respons
lofthous
et
al
care
choos
cytokin
ad
immun
respons
driven
certain
direct
interferon
gamma
ifn
may
ad
stimul
macrophag
addit
promot
cellmedi
adapt
immun
abba
lichtman
effici
produc
baculoviru
vector
function
dimer
shift
immunogen
balanc
cell
bovin
calv
takehara
et
al
ad
influenza
vlp
enhanc
antibodi
respons
case
vlp
alon
alreadi
result
protect
galarza
et
al
immun
reaction
helminth
involv
respons
drive
immun
respons
differenti
cell
product
heminthspecif
ige
antibodi
abba
lichtman
addit
may
therefor
help
vaccin
helminth
lofthous
et
al
baculovirusderiv
product
addit
cytokin
fulli
exploit
commonli
use
dna
vaccin
addit
costimul
baculovirusproduc
vaccin
report
baculovir
vector
mammalian
promot
drive
express
viral
gene
use
limit
number
vaccin
trial
candid
pseudorabi
viru
vaccin
express
glycoprotein
b
recombin
baculoviru
vector
mammalian
promot
result
seroconvers
immun
mice
aoki
et
al
intramuscular
inject
baculoviru
bv
express
glycoprotein
hepat
c
viru
control
cmv
immediateearli
promoterenhanc
provid
specif
humor
cellular
respons
facciaben
et
al
similar
result
obtain
carcinoembryon
antigen
cea
indic
type
vaccin
also
effect
tumor
addit
vesicular
stomati
viru
vsv
g
protein
baculoviru
envelop
increas
immunogen
experi
possibl
enhanc
viru
fusion
bacmam
tm
vector
also
use
produc
mutat
attenu
influenza
viru
mammalian
cell
deliveri
alter
gene
poomputsa
et
al
surprisingli
baculoviru
vector
influenza
hemagglutinin
gene
control
chicken
betaactin
promot
gave
similar
level
protect
wildtyp
baculoviru
lethal
influenza
challeng
intranas
immun
mice
abe
et
al
author
ascrib
induct
strong
innat
immun
respons
baculoviru
protect
mice
subsequ
lethal
challeng
influenza
viru
possibl
drawback
use
baculovirus
directli
vaccin
possibl
also
surfac
display
polyhedraincorpor
vector
accumul
antibaculoviru
antibodi
upon
repeat
vaccin
result
rapid
inactiv
subsequ
vaccin
type
pig
instanc
shown
produc
high
level
baculovirusneutr
antibodi
inject
baculoviru
bv
tuboli
et
al
solut
problem
could
design
multival
vaccin
sinc
baculovirus
take
larg
amount
foreign
dna
anoth
problem
use
baculoviru
particl
vaccin
rapid
degrad
complement
system
also
affect
gene
therapi
applic
pseudotyp
bv
vsv
glycoprotein
instead
result
reduct
complement
inactiv
tani
et
al
incorpor
human
decayacceler
factor
daf
complementregulatori
protein
bv
envelop
shown
protect
baculoviru
gene
therapi
vector
complementmedi
inactiv
huser
et
al
strategi
could
also
appli
vaccin
purpos
hiv
vlp
contain
gag
use
boost
immun
induc
dna
vaccin
jaffray
et
al
case
capsid
protein
envelop
viru
reason
subunit
vaccin
dna
vaccin
express
intracellularli
fragment
result
protein
present
mhc
complex
induc
cellular
immun
respons
way
natur
situat
intracellular
express
viral
gene
mimick
cell
respons
especi
action
cytotox
lymphocyt
ctl
crucial
defens
hiv
hiv
combin
vaccin
adenoviru
vaccinia
vesicular
stomat
viru
vector
use
immun
combin
boost
protein
subunit
test
phase
trial
human
cooney
et
al
graham
et
al
lubeck
et
al
luo
et
al
peral
et
al
zheng
viral
carrier
also
express
hiv
antigen
insid
cell
antigen
display
either
special
apc
cell
immun
system
aim
regimen
dnacarri
vaccin
protein
boost
regimen
therefor
induc
neutral
antibodi
cell
respons
nonvaccin
polici
exist
mani
anim
diseas
risk
vaccin
anim
may
protect
diseas
may
still
carrier
viru
case
outbreak
ring
vaccin
sometim
appli
largescal
vaccin
gener
allow
prerequisit
broader
use
anim
vaccin
develop
marker
vaccin
enabl
differenti
vaccin
infect
anim
especi
import
endem
diseas
anim
monitor
crucial
import
avoid
spread
viru
nonendem
region
host
speci
human
wild
anim
marker
vaccin
also
good
prospect
erad
anim
diseas
gener
van
aarl
purpos
marker
vaccin
give
herd
immun
reduc
suscept
transmiss
suffici
major
effect
control
anim
diseas
henderson
marker
vaccin
need
accompani
specif
diagnost
test
commonli
base
determin
serum
titer
viral
compon
absent
vaccin
present
pathogen
antibodi
rais
baculoviru
express
system
proven
use
produc
protein
subunit
marker
vaccin
also
recombin
polypeptid
diagnost
test
commerci
avail
csfv
vaccin
base
glycoprotein
marker
vaccin
antibodi
gener
enzymelink
immunosorb
assay
elisa
test
serum
antibodi
immunogen
surfac
protein
e
rn
use
discrimin
immun
anim
viru
carrier
langedijk
et
al
van
aarl
anoth
possibl
use
epitop
antigen
immun
other
diagnost
analysi
demonstr
csfv
van
rijn
et
al
coexist
subunit
vaccin
discrimin
diagnost
test
enabl
registr
csfv
vaccin
europ
marker
vaccin
also
use
immun
poultri
avian
influenza
crawford
et
al
monitor
presenc
viru
essenti
anim
immun
ha
hana
vaccin
could
screen
antibodi
viral
matrix
protein
similar
assay
develop
subunit
vaccin
one
discrimin
vsvinfect
immun
anim
marker
vaccin
base
glycoprotein
assay
nucleocapsid
protein
produc
insect
larva
parasit
genera
plasmodium
theileria
babesia
protozoan
blood
parasit
caus
malaria
theileriosi
babesiosi
parasit
complex
life
cycl
transmit
either
mosquito
tick
vector
candid
subunit
vaccin
parasit
roughli
separ
preblood
preerythrocyt
prelymphocyt
stage
vaccin
blood
stage
vaccin
transmissionblock
vaccin
multistag
vaccin
overview
parasit
subunit
express
baculoviru
insect
cell
system
vaccin
purpos
given
tabl
iv
comprehens
record
subunit
recombin
carrier
vaccin
develop
human
malaria
maintain
reed
vaccin
still
preclin
stage
sever
plasmodium
falciparum
vaccin
phase
phase
ii
trial
malaria
endem
countri
plasmodium
transmit
form
sporozoit
anophel
mosquito
vaccin
candid
base
circumsporozoit
protein
csp
aim
block
sporozoit
b
cell
respons
appear
essenti
protect
immun
base
csp
protein
csp
produc
insect
cell
minim
immunogen
test
volunt
herrington
et
al
altern
approach
experiment
csp
vaccin
facilit
cell
respons
phase
ii
trial
ballou
et
al
vaccin
includ
csp
display
hbsag
vlp
particl
modifi
vaccinia
ankara
viru
recombin
carrier
dna
vaccin
merozoit
extracellular
erythrocyteinvas
form
plasmodium
parasit
merozoit
surfac
protein
promis
mitchel
et
al
vaccin
candid
due
access
antibodi
expect
role
erythrocyt
invas
major
merozoit
surfac
protein
import
prebloodstag
candid
vaccin
homolog
epiderm
growth
factor
egf
antibodi
direct
protein
block
erythrocyt
invas
holder
blackman
plasmodium
cynomolgi
function
model
system
highli
similar
plasmodium
vivax
human
activ
ctermin
process
form
p
cynomolgi
produc
insect
cell
protect
primat
challeng
experi
perera
et
al
ctermin
matur
p
falciparum
also
success
express
insect
cell
use
ultrastructur
studi
chitarra
et
al
pizarro
et
al
test
human
trial
meanwhil
e
coliexpress
enter
phase
ii
clinic
trial
ballou
et
al
plasmodium
parasit
ookinet
stage
taken
mosquito
antigen
specif
stage
function
transmissionblock
subunit
vaccin
major
ookinet
surfac
antigen
plasmodium
berghei
express
b
mori
larva
preserv
conform
b
cell
epitop
lost
upon
express
e
coli
recombin
antigen
produc
insect
cell
block
oocyt
format
anophel
mosquito
fed
immun
mice
matsuoka
et
al
immunogen
recombin
protein
strongli
reduc
protein
express
secret
protein
remov
glycosylphosphatidylinositol
gpi
anchor
signal
martinez
et
al
protein
provid
good
exampl
loss
immunogen
express
membran
protein
secret
form
subunit
vaccin
base
plasmodiuminduc
erythrocyt
membran
protein
aim
block
vertic
transmiss
mother
child
matern
malaria
via
placenta
transmiss
involv
sequestr
p
falciparuminfect
erythrocyt
bind
chondroitin
sulphat
placenta
express
baculoviru
system
induc
inhibitori
antibodi
react
homolog
heterolog
protein
costa
et
al
parva
caus
agent
east
coast
fever
deadli
cattl
diseas
endem
larg
part
africa
immun
recombin
sporozoit
surfac
protein
aim
block
invas
lymphocyt
parasit
exampl
protein
easi
express
nativ
form
insect
cell
well
mani
system
insect
cell
express
low
level
contrast
expect
present
cell
surfac
similar
e
coliexpress
react
monoclon
antibodi
nativ
indic
fold
protein
correct
nene
et
al
sever
adapt
therefor
made
express
system
express
coupl
honeybe
mellitin
signal
instead
origin
signal
peptid
result
correct
rout
protein
cell
surfac
fold
still
optim
kaba
et
al
fusion
c
terminu
gfp
drastic
increas
express
level
result
recognit
conformationsensit
monoclon
antibodi
kaba
et
al
similar
effect
also
seen
part
protein
fuse
baculoviru
glycoprotein
surfac
display
vector
led
express
cell
surfac
baculoviru
bv
kaba
et
al
recombin
protein
c
termin
half
coupl
induc
high
level
sporozoiteneutr
serum
antibodi
show
protect
lethal
parva
challeng
doubleblind
placebocontrol
experi
kaba
et
al
kaba
et
al
next
phase
evalu
qualiti
experiment
vaccin
field
condit
countri
east
coast
fever
endem
babesia
speci
major
caus
parasitemia
cattl
dog
babesia
divergen
major
caus
bovin
babesiosi
europ
increas
incid
diseas
correl
increas
number
tick
ixodu
ricinu
transmit
parasit
b
divergen
also
respons
zoonot
immunocompromis
human
zintl
et
al
solubl
parasit
antigen
spa
bovin
canin
babesia
speci
develop
vaccin
clinic
manifest
dog
produc
mammalian
cell
infect
babesia
schetter
sever
babesia
antigen
express
baculoviru
express
system
develop
elisa
test
diagnosi
baculovirusexpress
babesia
radhaini
protein
shown
induc
protect
diseas
rat
igarashi
et
al
theileria
babesia
parasit
transmit
ioxid
tick
futur
candid
antiparasit
vaccin
may
combin
vaccin
direct
tick
vector
bishop
et
al
vaccin
may
tick
antigen
directli
expos
host
immun
system
vitellin
abund
b
microplu
egg
protein
tellam
et
al
cement
protein
involv
attach
tick
skin
host
conceal
antigen
also
give
good
result
b
microplu
gut
antigen
gavac
tm
result
bind
antibodi
taken
immun
anim
gut
transmembran
protein
willadsen
et
al
tick
known
immunomodul
host
secret
specif
immunomodul
transmit
parasit
also
profit
reduct
immun
respons
tick
vaccin
may
therefor
aim
reduc
chanc
transmiss
directli
affect
feed
process
interact
immunomodul
reduc
tick
popul
chaga
diseas
america
caus
trypanosoma
cruzi
found
human
dog
cat
rodent
cruzi
macrophageinvad
protozoan
complic
factor
develop
vaccin
immun
escap
autoimmun
due
molecular
mimickri
giron
et
al
macrophag
also
target
leishmania
parasit
use
complex
immun
evas
strategi
affect
host
cell
signal
olivi
et
al
immun
cruzi
tol
alik
protein
tolt
express
insect
cell
result
celldepend
antiparasit
activ
quanquin
et
al
leishmania
sever
candid
subunit
vaccin
antigen
protect
potenti
identifi
includ
surfac
protein
coler
reed
protein
express
baculoviru
vector
insect
cell
helminth
parasit
worm
seriou
threat
human
anim
health
worldwid
divid
annelida
segment
worm
platyhelminth
flatworm
includ
fluke
nematoda
roundworm
worm
complex
life
cycl
often
involv
one
host
helminth
vari
wide
among
popul
vaccin
competit
far
chemic
broad
spectrum
antihelminth
bo
schetter
helminth
may
also
modul
immun
system
exemplifi
filari
nematod
present
million
human
worldwid
caus
river
blind
exampl
filari
nematod
difficult
combat
modul
cell
respons
lead
chronic
helminth
infect
review
hoerauf
et
al
cell
modul
restrict
respons
filari
larva
also
affect
allergi
respons
pathogen
vaccin
modul
antigenspecif
cell
also
apc
affect
immun
respons
gener
exampl
baculov
irusex
press
helminth
protein
bee
n
test
immuniz
ation
stud
i
tabl
iv
ever
bacu
loviru
expr
sion
syst
may
valuabl
tool
parasit
wor
ms
illustr
ate
th
e
follow
exampl
baculov
irusderi
ved
subu
nit
vaccin
again
liver
fluke
fasciola
hepati
ca
base
proc
athep
confer
red
prot
ection
rat
contra
yea
texpress
ed
protein
whic
h
confer
prote
ction
reszk
et
al
bilhar
zia
schisto
omia
caus
sch
istosoma
spp
platyh
elminth
blood
parasit
human
trop
ical
area
sever
sch
istoso
gene
express
nsect
cell
prim
arili
anal
ysi
en
zymat
functi
on
larg
sub
unit
calpain
prod
uce
bac
uloviru
expr
sion
system
reduc
ed
worm
burden
n
mice
hotamitchel
et
al
antigen
tapeworm
taenia
solium
express
baculoviru
vector
diagnost
purpos
lee
et
al
levin
et
al
mani
exampl
literatur
immun
recombin
protein
produc
baculovirusinsect
cell
express
system
confer
good
protect
infecti
diseas
subunit
vaccin
develop
begin
care
identif
antigen
relat
whether
neutral
adapt
immun
respons
rais
particular
protein
natur
infect
select
open
read
frame
orf
antigen
clone
keep
flank
dna
sequenc
minimum
best
achiev
proofread
pcr
enzym
sequenc
around
atg
translat
start
site
best
modifi
polyhedrin
gene
wildtyp
baculoviru
least
adenosin
residu
posit
chang
et
al
tag
may
ad
facilit
purif
prefer
way
subsequ
remov
tag
requir
vlp
purifi
centrifug
transmembran
glyco
protein
best
produc
secret
form
remov
tmr
increas
express
level
howev
may
occasion
affect
fold
protein
altern
approach
fuse
immunogen
domain
envelop
protein
vector
lack
chitinas
vcathepsin
gene
prefer
express
envelop
protein
prepar
seed
stock
care
taken
keep
viru
passag
number
low
use
multipl
infect
minim
format
di
care
check
puriti
recombin
bacmid
plaqu
purifi
recombin
virus
pcr
crucial
avoid
loss
recombin
viru
subsequ
passag
due
empti
vector
outcompet
recombin
two
baculovirusproduc
product
approv
veterinari
practic
name
two
vaccin
classic
swine
fever
consist
surfac
glycoprotein
vaccin
market
although
nonvaccin
polici
still
exist
confid
type
subunit
vaccin
grow
well
possibl
registr
therebi
increas
likelihood
vaccin
kind
appear
market
expect
increas
number
product
may
expand
human
applic
registr
trival
recombin
influenza
vaccin
phase
iii
clinic
trial
human
unit
state
complet
recent
achiev
therapeut
anticanc
vaccin
vaccin
prostat
cancer
may
readili
accept
view
sever
side
effect
anticanc
drug
irradi
techniqu
applic
baculoviru
display
bacmam
tm
vector
vaccin
infecti
diseas
may
appli
futur
anim
use
foreign
protein
incorpor
vaccin
target
antigen
vaccin
human
use
like
distant
futur
safeti
consider
baculoviru
express
system
compet
cheaper
product
system
wide
use
scaleup
easili
e
coli
yeast
tabl
good
protect
level
achiev
commerci
interest
switch
expens
insect
cell
system
case
though
fold
posttransl
modif
crucial
epitop
format
baculovirusinsect
cell
system
versatil
express
system
mani
candid
vaccin
success
test
altern
method
provid
develop
dna
vaccin
technolog
recombin
carrier
vaccin
base
vaccinia
adenoviru
bacmam
tm
vector
tabl
ii
method
prone
induc
cellular
immun
respons
mani
protein
subunit
vaccin
combin
primari
vaccin
intracellular
deliveri
system
recombin
carrier
vaccin
dna
vaccin
bacmam
tm
vector
follow
boost
immun
recombin
protein
subunit
appear
promis
approach
aim
cellular
humor
immun
respons
approach
strengthen
addit
recombin
cytokin
drive
immun
respons
specif
direct
major
challeng
broaden
array
viral
vaccin
produc
insect
cell
develop
effect
vaccin
complex
organ
protozoan
parasit
multicellular
worm
baculoviru
express
system
also
hold
promis
increas
insight
immunolog
lead
new
method
vaccin
product
deliveri
accompani
wealth
genom
proteom
data
mani
new
gener
vaccin
expect
within
forese
futur
acknowledg
thank
manon
cox
dick
schaap
stephen
kaba
assist
section
viral
vaccin
parasit
vaccin
malaria
vaccin
respect
christina
van
hout
verifi
tabl
iii
vlak
review
manuscript
help
suggest
